K-numberK241179
Device nameRhythm Express Remote Cardiac Monitoring System (RX-1 mini)
ApplicantVivaQuant, Inc.
Product codeQYX
Device classClass II
Decision dateJul 11, 2025
DecisionSubstantially Equivalent
Regulation870.1025
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The RX-1 mini Rhythm Express Remote Cardiac Monitoring System is a wearable device for patients over 10 kg with cardiac disease or cardiac symptoms. It continuously records two-channel ECG data, detects arrhythmias using an on-board algorithm, and transmits recorded cardiac activity to a monitoring center within 1-7 minutes for physician review. The device does not deliver therapy, administer drugs, or provide diagnostic interpretations.

Technological characteristics

The RX-1 mini shares the same cardiac monitoring modes, ECG algorithm design, ECG performance standard, 2-channel 4-lead input, heart rate range, and event storage as the predicate RX-1 device. Key differences include smaller housing and lighter weight, new patient contact material (lead), simplified user interface with LED and haptic feedback, additional arrhythmia detections (SVEs, VT, SVT), shorter ECG lead length, smaller battery with magnetic charger, and addition of Wi-Fi and Bluetooth interfaces.

Test standards cited

Testing followed IEC 60601-1:2005, IEC 60601-1-2:2014, IEC 60601-1-6:2010, IEC 60601-1-11:2015, IEC 60601-2-47:2012, IEC 62304:2006, IEC 62366-1:2015, IEEE C63.27-2017, IEEE C95.1-2005, ISO 10993 series (biocompatibility), ISO 14971:2019 (risk management), and ANSI AAMI standards for ECG electrodes and cardiac rhythm measurement algorithms.

Substantial equivalence argument

The RX-1 mini has identical intended use and indications for use as the predicate RX-1 device. Although the mini version is smaller, lighter, has enhanced detection capabilities (SVE, VT, SVT), simplified user interface, and new wireless connectivity, these differences do not raise new safety or effectiveness questions because the core ECG monitoring, analysis algorithm, and data transmission functions are substantively preserved. Performance testing demonstrates the RX-1 mini meets the same performance specifications as the predicate, establishing safety and effectiveness equivalence.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →